Promising Results from iMMagine-1 Anito-Cel Study | Gurbakhash Kaur, MD | EHA 2025 #myeloma

Promising Results from iMMagine-1 Anito-Cel Study | Gurbakhash Kaur, MD | EHA 2025 #myeloma
What is being done to enhance the response of CAR-T cell therapy and bispecific antibody therapy?
Assessing the Shift From mSMART V3.0 to V4.0 | Jorge A Hurtado Martinez, MD | EHA 2025 #myeloma
Etentamig: A New BCMA Bispecific Antibody Showing Safety & Promise | Muhamed Baljevic, MD | #EHA2025
The Importance of Joining Clinical Trials | Sunil Gupta, FCRPath, MRCP, DNB | EHA 2025 #myeloma
The Importance of Joining Clinical Trials | Sunil Gupta, FCRPath, MRCP, DNB
Diagnosing Myeloma? Don’t Skip This Critical Amyloidosis Test! Jahanzaib Khwaja, MD, FRCPath
What is immune effector cell associated hematotoxicity (ICHAT)? Which myeloma therapies are associated with ICHAT? How is ICHAT managed?
New Hope for MRD Recurrence? Daratumumab Proof-of-Concept Study | Krzysztof Jamroziak, MD | #EHA2025